Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Iovance Biotherapeutics's enterprise value is $2,045.0 Mil.
Iovance Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-311.2 Mil. Therefore, Iovance Biotherapeutics's EV-to-EBITDA for today is -6.57.
The historical rank and industry rank for Iovance Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
IOVA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.59 Med: -3.79 Max: -0.66
Current: -6.57
During the past 13 years, the highest EV-to-EBITDA of Iovance Biotherapeutics was -0.66. The lowest was -9.59. And the median was -3.79.
IOVA's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.295
vs IOVA: -6.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Iovance Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Iovance Biotherapeutics's share price for today is $5.175.
Iovance Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's EV-to-EBITDA falls into.
Iovance Biotherapeutics's current Enterprise Value is $2,045.0 Mil.
Iovance Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-311.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (IOVA) has a EV-to-EBITDA of -6.57 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Iovance Biotherapeutics. According to the industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 398 companies in the Biotechnology industry.
Is Iovance Biotherapeutics' EV-to-EBITDA too high?
Iovance Biotherapeutics' current EV-to-EBITDA is -6.57. Based on the distribution chart, Iovance Biotherapeutics ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Iovance Biotherapeutics has a GF Score™ of 45/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' EV-to-EBITDA compare to SNDX and GLUE?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #999999 out of 398 companies for EV-to-EBITDA. This places Iovance Biotherapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 12.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.30, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Iovance Biotherapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current EV-to-EBITDA is -6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is $19.12, compared to a current price of $5.18 — trading 72.9% below its estimated fair value. The current EV-to-EBITDA is -6.57. Iovance Biotherapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current EV-to-EBITDA is -6.57 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $5.18 is trading 72.9% below its estimated GF Value™ of $19.12.
GuruFocus considers Iovance Biotherapeutics to be Significantly Undervalued.
Key valuation signals for IOVA:
EV-to-EBITDA: -6.57
GF Value™: $19.12 vs. price of $5.18 (72.9% below fair value)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
45GF Score
Get the complete analysis for IOVA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
